1. Home
  2. TCBK vs TSHA Comparison

TCBK vs TSHA Comparison

Compare TCBK & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TriCo Bancshares

TCBK

TriCo Bancshares

HOLD

Current Price

$58.20

Market Cap

2.0B

Sector

Finance

ML Signal

HOLD

Logo Taysha Gene Therapies Inc.

TSHA

Taysha Gene Therapies Inc.

HOLD

Current Price

$5.89

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TCBK
TSHA
Founded
1975
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.7B
IPO Year
1995
2020

Fundamental Metrics

Financial Performance
Metric
TCBK
TSHA
Price
$58.20
$5.89
Analyst Decision
Buy
Strong Buy
Analyst Count
5
8
Target Price
$54.60
$11.63
AVG Volume (30 Days)
579.3K
2.9M
Earning Date
04-23-2026
05-06-2026
Dividend Yield
2.87%
N/A
EPS Growth
6.94
5.56
EPS
1.04
N/A
Revenue
$53,445,000.00
$9,773,000.00
Revenue This Year
$12.03
N/A
Revenue Next Year
$4.47
$1,152.42
P/E Ratio
$55.81
N/A
Revenue Growth
4.12
17.28
52 Week Low
$39.84
$2.54
52 Week High
$61.71
$7.30

Technical Indicators

Market Signals
Indicator
TCBK
TSHA
Relative Strength Index (RSI) 56.91 44.20
Support Level $48.57 $5.28
Resistance Level $61.71 $6.01
Average True Range (ATR) 1.39 0.47
MACD -0.28 -0.06
Stochastic Oscillator 57.33 26.18

Price Performance

Historical Comparison
TCBK
TSHA

About TCBK TriCo Bancshares

TriCo Bancshares is a California corporation organized to act as a bank holding company for Tri Counties Bank. The Bank is a California-chartered bank that is engaged in the general commercial and retail banking business in California counties. The Bank provides a breadth of personal, small business, and commercial financial services, including accepting demand, savings and time deposits and making small business, commercial, real estate, and consumer loans, as well as a range of treasury management services and other customary banking services including safe deposit boxes at some branches. The company's primary source of revenue is the net interest income.

About TSHA Taysha Gene Therapies Inc.

Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.

Share on Social Networks: